Precose

Physical Activity, Type 2 Diabetes, Diet
Treatment
20 Active Studies for Precose

What is Precose

AcarboseThe Generic name of this drug
Treatment SummaryAcarbose is a medication used to help manage type 2 diabetes. It works by blocking the breakdown of complex carbohydrates in the intestines and preventing their absorption into the bloodstream. This helps to reduce post-meal spikes in blood sugar and insulin levels. Acarbose is usually taken three times a day and may cause some gastrointestinal side effects. It was first approved by the FDA in 1995 and is one of two approved alpha-glucosidase inhibitors.
Precoseis the brand name
image of different drug pills on a surface
Precose Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Precose
Acarbose
1996
67

Effectiveness

How Precose Affects PatientsAcarbose is a type of medication that prevents carbohydrates from being broken down and absorbed by the body, helping to keep blood sugar levels in check. It should be taken with the first bite of each meal, three times a day. Taking acarbose with other antidiabetic drugs can increase the risk of hypoglycemia, so patients should be aware of the symptoms and how to treat it. In rare cases, taking acarbose can lead to intestinal issues such as severe diarrhea, mucus discharge, or rectal bleeding. If this happens, treatment should be stopped and medical advice should be sought.
How Precose works in the bodyAcarbose works by blocking enzymes that break down sugars in your intestines. This prevents your body from absorbing the sugars from food, which helps lower your blood sugar and insulin levels after eating. Acarbose is a complex sugar molecule that attaches to and blocks the alpha-glucosidases and alpha-amylase enzymes in your intestines. These enzymes are responsible for breaking down carbohydrates into smaller molecules so they can be absorbed by the body. By blocking these enzymes, acarbose helps to regulate blood sugar levels.

When to interrupt dosage

The proposed dosage of Precose is contingent upon the determined condition, for example, Physical Activity, Diet and Type 2 Diabetes. The amount of dosage is dictated by the mode of delivery listed in the table beneath.
Condition
Dosage
Administration
Physical Activity
25.0 mg, 50.0 mg, , 100.0 mg
, Oral, Tablet, Tablet - Oral
Type 2 Diabetes
25.0 mg, 50.0 mg, , 100.0 mg
, Oral, Tablet, Tablet - Oral
Diet
25.0 mg, 50.0 mg, , 100.0 mg
, Oral, Tablet, Tablet - Oral

Warnings

Precose has eight contraindications and should not be taken in coordination with the conditions indicated in the table below.Precose Contraindications
Condition
Risk Level
Notes
Diabetic Ketoacidosis
Do Not Combine
Intestinal Diseases
Do Not Combine
colonic ulceration
Do Not Combine
Crohn's Disease
Do Not Combine
Cirrhosis
Do Not Combine
Intestinal Obstruction
Do Not Combine
Intestinal Obstruction
Do Not Combine
Severe Hypersensitivity Reactions
Do Not Combine
Acarbose may interact with Pulse Frequency
There are 20 known major drug interactions with Precose.
Common Precose Drug Interactions
Drug Name
Risk Level
Description
Ketotifen
Minor
The risk or severity of thrombocytopenia can be increased when Acarbose is combined with Ketotifen.
2,4-thiazolidinedione
Moderate
The risk or severity of hypoglycemia can be increased when Acarbose is combined with 2,4-thiazolidinedione.
AICA ribonucleotide
Moderate
The risk or severity of hypoglycemia can be increased when Acarbose is combined with AICA ribonucleotide.
AMG-222
Moderate
The risk or severity of hypoglycemia can be increased when Acarbose is combined with AMG-222.
Acetohexamide
Moderate
The risk or severity of hypoglycemia can be increased when Acarbose is combined with Acetohexamide.
Precose Toxicity & Overdose RiskTaking too much acarbose could cause uncomfortable side effects, such as bloating, gas, and stomach pain. If an overdose is suspected, patients should try to avoid eating foods with carbohydrates for 4-6 hours.
image of a doctor in a lab doing drug, clinical research

Precose Novel Uses: Which Conditions Have a Clinical Trial Featuring Precose?

196 active clinical trials are currently being conducted to evaluate the potential of Precose in improving Physical Activity, Type 2 Diabetes and Dietary habits.
Condition
Clinical Trials
Trial Phases
Type 2 Diabetes
167 Actively Recruiting
Not Applicable, Phase 1, Phase 2, Phase 3, Phase 4, Early Phase 1
Diet
5 Actively Recruiting
Not Applicable, Phase 1
Physical Activity
24 Actively Recruiting
Not Applicable, Phase 1, Phase 2

Precose Reviews: What are patients saying about Precose?

5Patient Review
5/19/2011
Precose for Type 2 Diabetes Mellitus
This medication has been nothing short of a medical miracle for me. I was close to becoming insulin-dependent, but thanks to this medication (among others), my blood sugar levels never go over 200! I'm no longer afraid to eat.
5Patient Review
6/11/2008
Precose for Type 2 Diabetes Mellitus
This medication has been effectively regulating my blood sugar levels. I haven't experienced any negative side effects, which is great.
5Patient Review
5/1/2015
Precose for Type 2 Diabetes Mellitus
In the four weeks that I've been taking this medication, it has effectively lowered my blood sugar levels after high carb meals. It's been a lifesaver for me.
4.7Patient Review
10/18/2009
Precose for Type 2 Diabetes Mellitus
I've been on Precose for two years and have had few side effects when sticking to a proper diet. I get more bloating and gas when consuming starches like white breads, potatoes, pasta, and rice. So long as I'm careful with my food choices, though, this isn't much of an issue anymore.
2.7Patient Review
2/7/2011
Precose for Type 2 Diabetes Mellitus
I had a lot of the listed side effects, including bloating, gas, upset stomach, and a rash. I wasn't able to finish the treatment because of how bad it was.
1Patient Review
9/12/2009
Precose for Type 2 Diabetes Mellitus
I was on my second month of this medication when I started having bad diarrhea. My doctor advised me to stop taking it altogether. I'm willing to give it another try, but I haven't had great results so far.
1Patient Review
1/22/2016
Precose for Type 2 Diabetes Mellitus
Unfortunately, this medication only worked as a laxative for me. I would experience gas, bloating, and other issues after taking it.
1Patient Review
12/3/2007
Precose for Type 2 Diabetes Mellitus
1Patient Review
7/18/2009
Precose for Type 2 Diabetes Mellitus
I experienced terrible bloating, abdominal cramps, and alternating constipation/diarrhea while using this medication. After four weeks, I stopped taking it and felt better within another four weeks.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about precose

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is Precose used for?

"Precose is a medication used to treat type 2 diabetes. It may be used in combination with insulin or other diabetes medications. Precose is available in generic form."

Answered by AI

When should I take Precose?

"To use Precose, take it by mouth as directed by your doctor. The usual dosage is three times daily, with the first dose taken with the first bite of a meal. The dosage is based on your medical condition and response to treatment."

Answered by AI

What acarbose is used for?

"Acarbose is a medication used to treat type 2 diabetes. Normally, your pancreas releases insulin into the blood stream after you eat. Insulin is used by all the cells in your body to help turn the food you eat into energy."

Answered by AI

What drug class is Precose?

"The drug slows down the breakdown of carbohydrates into sugar, which in turn helps to control blood sugar levels."

Answered by AI

Clinical Trials for Precose

Image of KPNC Division of Research in Pleasanton, United States.

MetSense Risk Flag for Type 2 Diabetes

18+
All Sexes
Pleasanton, CA
People with serious mental illness have high risk for type 2 diabetes due to multiple risk factors, including the metabolic side effects of psychotropic medications that are used to treat these conditions. Type 2 diabetes is preventable through lifestyle and pharmacological interventions, but many people with serious mental illness do not receive regular screening for type 2 diabetes risk. In many health care settings, clinical pharmacists are increasingly managing patients with serious mental illness and have expertise in monitoring the metabolic side effects of psychotropic medications. This study evaluates the feasibility and acceptability of using a diabetes prediction model that is based on electronic health record data (the MetSense risk flag) to alert clinical pharmacists about patients who are at high diabetes risk, prompting these clinicians to prioritize diabetes risk management services.
Waitlist Available
Has No Placebo
KPNC Division of ResearchEsti Iturralde, PhD
Image of University of California, Los Angeles in Los Angeles, United States.

Tailored DPP for Prediabetes

17 - 25
All Sexes
Los Angeles, CA
The goal of this study is to enhance reach and uptake of diabetes prevention among young adults, with a focus on recruiting underserved and high-need students who face additional challenges, including food and financial insecurity. The specific aims are: Aim 1 - Evaluate the efficacy of an AYA-tailored version of the UC DPP for mitigating type 2 diabetes risk (i.e., weight change) in a pre/post pilot trial. The investigators hypothesize that the AYA-tailored intervention will be effective at producing 5% weight loss from baseline to program completion (at 9-months). Aim 2 - Assess the feasibility and acceptability of an AYA-tailored version of the UC DPP program. The investigators hypothesize that it will be feasible to recruit the desired number of participants given proposed innovative outreach strategies, and that the AYA-tailored intervention will be deemed acceptable to participants both qualitatively and in regards to their retention in the program at rates similar to the larger UC DPP. The investigators will recruit 80 UCLA undergraduate students. Participants will be asked to complete a brief screening online form to assess eligibility and to collect contact information. The PI and/or Research Assistants (RAs) will reach out to eligible participants to obtain informed consent and enroll them in the pilot trial. The investigators will randomize participants to the tailored DPP cohort vs control cohort. Control participants will be offered the opportunity to participate in the tailored DPP in the following academic year. The tailored DPP intervention will be online and asynchronously. Participants will be asked to complete the intervention lessons on their own time. Each lesson typically takes on average 15 minutes to complete. Control group will receive each intervention materials via e-mail for participants to review on their own time and will receive acceptability surveys. The interventions for the control group will be remote. A research assistant will meet with control participants via Zoom to explain the intervention materials. Control group will receive access to a study habits intervention, alcohol use intervention, and financial literacy intervention. At the end of each quarter (Fall, Winter, and Spring), both control and intervention participants will receive an email with a unique link to a brief REDCap survey to ascertain acceptability of sessions/lessons. Furthermore, participants will complete baseline and 9-month follow-up assessments. Participants will complete a 30 minute questionnaire and height/weight measurements will be collected by a RA. Participants will be asked to self-report weight and physical activity at the end of the fall and winter quarter; data will be collected via brief REDCap survey.
Recruiting
Has No Placebo
University of California, Los AngelesLauren E Wisk, PhD
Have you considered Precose clinical trials? We made a collection of clinical trials featuring Precose, we think they might fit your search criteria.Go to Trials
Image of The Worship Center Cristian Church in Birmingham, United States.

Black Impact for Heart Health

18+
Male
Birmingham, AL
The goal of this clinical trial is to evaluate the implementation and effectiveness of the Black Impact program-a church-based cardiovascular health (CVH) intervention-in Black men aged 35-70 who are at risk for heart disease, diabetes, obesity, and related conditions. The main questions this study aims to answer are: * Does participation in the Black Impact program improve cardiovascular health metrics (e.g., blood pressure, cholesterol, blood sugar) and health behaviors among Black men at The Worship Center Christian Church (TWC)? * What factors influence the adoption, delivery, and sustainability of the Black Impact program in a faith-based setting? Researchers will compare an immediate-start intervention group and a delayed-start (waitlist control) group to assess both short-term health outcomes and program implementation factors. Participants will: * Attend a 90-minute weekly session for 24 weeks, including 45 minutes of physical activity led by a certified trainer and 45 minutes of health education delivered by trained coaches. * Receive one-on-one support from a community health worker to reduce barriers to care and engage with primary care. * Complete biometric health screenings and surveys at baseline, 12 weeks, and 24 weeks to assess clinical and behavioral outcomes. * Use a smartwatch, blood pressure cuff, and other tools to track progress in real time. * Participate in exit focus groups or interviews to share feedback about the intervention. * A subset of TWC leaders and interventionists (N=15) will also be interviewed to assess implementation, resource needs, and sustainability. This study uses the RE-AIM framework to assess Reach, Effectiveness, Adoption, Implementation, and Maintenance, and aims to inform scalable strategies for improving CVH among Black men in trusted community settings.
Waitlist Available
Has No Placebo
The Worship Center Cristian Church
Have you considered Precose clinical trials? We made a collection of clinical trials featuring Precose, we think they might fit your search criteria.Go to Trials
Image of University of British Columbia - Okanagan in Kelowna, Canada.

Estrogen and Testosterone for Gender Differences in Physiology

18 - 40
All Sexes
Kelowna, Canada
Due to historical exclusion of females from research, there are gaps in the understanding of female physiology, how it differs from males, and how sex-specific hormones contribute. As a result, many diagnoses and treatments are based on male physiology and may not be appropriate or effective for females. Females consistently experience greater risk and report worse neurological outcomes in many diseases, including stroke, cardiac arrest, and dementia. As research in females progresses, differences between sexes and changes throughout the lifespan (e.g., puberty, menopause) highlight the importance of understanding the effects of sex and sex-specific hormones on the body. The brain is arguably the most important organ in the body, consuming 20% of the body's total energy. Previous research supports higher blood flow to the brain in females, and research in animals suggests hormones such as estrogen, progesterone, and testosterone are responsible. However, it is extremely difficult to isolate these hormones in humans, due to natural fluctuations (i.e., menstrual cycle). Therefore, the investigators plan to explore the direct role of these sex-specific hormones in regulating blood flow to the brain by blocking hormone production in healthy males and females and giving back testosterone and estrogen, respectively. The investigators will then conduct a range of tests to look at blood flow to the brain at rest and during various stressors. This research will provide crucial insight into how males and females differ in regulation of brain blood flow and inform new treatments and therapies to a wide range of brain injuries and diseases, improving outcomes and reducing the sex disparity in clinical pathways.
Waitlist Available
Has No Placebo
University of British Columbia - OkanaganPhilip Ainslie, PhD
Image of Exercise Metabolism and Inflammation Laboratory in Okanagan, Canada.

Aerobic Exercise with Blood Flow Restriction for Type 2 Diabetes

19 - 64
All Sexes
Okanagan, Canada
The goal of this trial is to learn if blood flow restriction training with treadmill walking is possible for individuals living with type 2 diabetes. It will also learn about how the blood flow restriction with treadmill walking could improve health. The main questions it aims to answer are: Is 6 weeks of treadmill walking with blood flow restriction reasonable for people with type 2 diabetes to perform? Does treadmill walking with blood flow restriction training help manage type 2 diabetes better than just treadmill walking? Researchers will compare treadmill walking with blood flow restriction to treadmill walking without blood flow restriction to see if blood flow restriction works to manage type 2 diabetes based on fitness and blood sugar levels. Participants will: Perform treadmill walking with or without blood flow restriction for 96 minutes a week for 6 weeks. Visit the lab before and after the exercise for tests and questionnaires.
Waitlist Available
Has No Placebo
Exercise Metabolism and Inflammation Laboratory (+2 Sites)Martin Senechal, PhD
Have you considered Precose clinical trials? We made a collection of clinical trials featuring Precose, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security